Infectin Transduction Enhancer

Product Description

Actin-Modulating Technology for Enhanced Viral Vector and Nanoparticle Delivery

Virongy’s Infectin™ is a proprietary transduction enhancer developed to improve the intracellular delivery of viral vectors, nanoparticles, exosomes, and other therapeutic cargo. Unlike conventional transduction enhancers that primarily increase particle attachment, Infectin™ works by transiently modulating cortical actin dynamics—the natural intracellular barrier that limits efficient entry and trafficking of many biological delivery systems.

This unique mechanism promotes productive intracellular transport following particle attachment, leading to substantial improvements in gene delivery efficiency while reducing the amount of viral vector required for successful transduction.

Built upon more than a decade of research into the role of the actin cytoskeleton during viral infection, Infectin™ is designed to improve the performance of modern gene therapy, cell therapy, and nanoparticle delivery workflows.

Scientifically Validated Mechanism

In a recent publication in Science Advances, Virongy’s researchers identified a novel class of actin-derived bioactive peptides (“Actinators”) that transiently modulate actin dynamics by interacting with actin-binding proteins involved in cytoskeletal remodeling.

These peptides were shown to:

• Increase lentiviral and retroviral transduction by 20-30 fold
• Enhance viral entry into difficult-to-transduce primary cells
• Improve AAV uptake
• Increase exosome uptake by up to 10-fold
• Promote intracellular delivery without activating target cells
• Facilitate productive intracellular trafficking by temporarily overcoming the cortical actin barrier

These findings establish a new class of intracellular delivery enhancers with applications spanning gene therapy, CAR-T manufacturing, viral vector production, exosome therapeutics, and nanoparticle delivery.

Applications

Infectin™ can significantly improve delivery efficiency for numerous research and therapeutic workflows including:

• Lentiviral vector transduction
• Retroviral vector transduction
• AAV vector delivery
• Exosome uptake studies
• Lipid nanoparticle (LNP) delivery
• Viral rescue from clinical or research samples
• CAR-T cell manufacturing
• CRISPR gene editing workflows
• Cell engineering
• Gene therapy development
• Antiviral drug screening
• Difficult-to-transduce primary cells

Why Researchers Choose Infectin™

Mechanistically different

Rather than simply increasing viral attachment, Infectin™ enhances intracellular trafficking by transiently modulating cortical actin dynamics.

Higher transduction efficiency

Researchers frequently observe 5-30× improvements, depending on vector type, target cells, and experimental conditions.

Reduce vector requirements

Higher transduction efficiency can reduce the amount of expensive viral vector needed to achieve target expression levels.

Broad compatibility

Compatible with numerous enveloped viral vectors, AAV, exosomes, and nanoparticle delivery systems.

NEW — Turbo-Infectin™

Dual-Action Transduction Enhancement

Turbo-Infectin™ combines Virongy’s proven Infectin™ technology with a proprietary viral attachment-enhancing formulation to maximize delivery efficiency through two complementary mechanisms.

Step 1 – Enhanced Particle Attachment

Turbo-Infectin™ increases the interaction between negatively charged viral particles or nanoparticles and the cell surface, promoting greater particle binding and cellular uptake.

Step 2 – Enhanced Intracellular Transport

Following attachment, Infectin™ transiently modulates cortical actin dynamics to facilitate productive intracellular trafficking and nuclear delivery.

The result is a comprehensive transduction enhancement strategy that improves both particle entry and post-entry intracellular transport, producing higher overall delivery efficiencies than either mechanism alone.

Turbo-Infectin™ is ideal for:

• Lentiviral vectors
• Retroviral vectors
• AAV vectors
• Lipid nanoparticles
• Exosomes
• Gene editing platforms
• Cell therapy manufacturing
• Difficult primary cells

Important

• Once thawed, Infectin^TM should be stored at 4^oC, and is stable for 3 months.
• Do not re-freeze and do not leave Infectin^TM at room temperature.
• Infectin^TM viral infection enhancer works with most cell lines to enhance viral infection. On average, Infectin^TM enhances productive viral infection by 5- to 30-fold*.
• Infectin^TM is formulated at 10X concentration. For best results, when using Infectin^TM for the first time, start with a higher concentration (final Infectin concentration may be 2X or 3X). The lowest effective dosage can be determined through a titration experiment (final Infectin^TM concentration may be as low as 1X).
  

(*The degree of enhancement is affected by the type of virus and cells. Enhancement is strongest for enveloped viruses entering cells via membrane fusion.)